Brendan Technologies, Inc. Delivers New Analysis Software to Big Pharma That Offers "Quantum Leap" for Drug Development Testing.

Pre-Release Version of STATLIA[R] Quantum for the Analysis and Processing of Immunoassay and Bioassay Testing Technologies

CARLSBAD, Calif. -- Brendan Technologies, Inc. (OTCBB:BDTE.OB, http://www.brendan.com) has begun placing a pre-release version of its new assay analysis software in several big pharma companies. The software, STATLIA([R]) Quantum, offers a "quantum leap" advancement in analysis software for the analysis and processing of immunoassay and bioassay testing technologies, which are critical to the drug development and drug release process.

The company is also forming an Advisory Committee with the biopharmaceutical companies that are using the advanced STATLIA Quantum to provide a direct dialogue between participating companies' laboratories and Brendan's development staff, in order to ensure that all custom needs and regulatory requirements are addressed in the software.

Brendan has been an innovative leader in the computation and analysis of immunoassays and bioassays, developing and perfecting several new methodologies and analytical processes. Designed on a .NET platform, STATLIA Quantum provides an advanced graphical presentation of the analysis and an automated design to save time in the drug development process by increasing productivity and improving assay performance through better accuracy and analysis.

"Our company has been at the forefront of many of the new computational and analysis methods used in immunoassay and bioassay analysis," said John Dunn, PhD, Chief Executive Officer of Brendan Technologies. "STATLIA Quantum allows us to combine our software's advanced computational analysis with the automation, graphical tools, and data visualization necessary for today's biopharmaceutical laboratories."

One of the industry's leading experts in the field of immunoassay and bioassay testing, Dr. Dunn serves as an IBC Life Sciences instructor teaching comprehensive training courses on the subject of "Analyzing Biological Assays" to the biopharmaceutical industry.

About Brendan Technologies, Inc.

Brendan Technologies, a developer and marketer of innovative analytical software, is actively providing software solutions to improve the accuracy, quality control, workflow, and regulatory compliance of immunoassay and bioassay testing in laboratories in the biopharmaceutical, clinical, research, veterinarian and agricultural industries. The Company's customers, many of whom are Fortune 1000 organizations, represent some of the largest corporations in their respective fields. Brendan Technologies is continually redesigning and expanding its product lineup to better capitalize on the growing demand of its target markets for more advanced software.

Background on Immunoassay Testing

Immunoassays are one of the world's largest and fastest growing testing technologies used to diagnose diseases, discover new chemical entities and biological products, provide vital data in the development of drugs in FDA clinical trials, and assist in quality control of drug manufacturing and drug screening. It is also one of the largest technologies used in environmental testing. Currently, $50 billion is spent globally on immunoassay testing, with approximately $1 billion of that being spent on immunoassay software.

Immunoassays are highly sensitive and specific chemical tests used to detect and quantify extremely minute substances in blood, body fluid and other biological samples, using an immunological reaction. These tests measure the formation of antibody-antigen complexes and detect them via an indicator reaction. Their high specificity results from the use of antibodies and purified antigens as reagents. High sensitivity is achieved by using an indicator system that results in amplification of the measured product. Immunoassays may be qualitative (positive or negative) or quantitative (amount measured).

FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-KSB, as amended, for the most recently ended fiscal year. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward- looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.